Dr.ย Mosheย Inbar
MD (Doctor of Medicine)
Senior Medical Oncologist
corporate_fareTel Aviv Sourasky Medical Center (Ichilov), Tel Aviv
Moshe Inbar
MD (Doctor of Medicine)
Prof. Moshe Inbar is a highly experienced senior medical oncologist at Tel Aviv Sourasky Medical Center, one of Israel's leading academic hospitals. Over more than three decades of clinical practice, he has built a strong specialisation in gastrointestinal cancers, including colorectal, gastric and pancreatic cancer, as well as breast and urogenital malignancies.
Prof. Inbar is affiliated with Tel Aviv University and has been an active contributor to oncology research covering gastric, oesophageal and rectal cancers, chemotherapy and biomarker-driven treatment strategies. His clinical approach is multidisciplinary โ evaluating tumour biology, molecular markers, disease stage and prior treatment history before recommending systemic therapy. He regularly advises on chemotherapy, targeted therapy and immunotherapy suitability, and is frequently consulted for second opinions by patients with advanced or complex gastrointestinal cancers. International patients seeking expert review of colorectal, gastric or pancreatic cancer treatment plans can access Prof. Inbar's consultation through CancerFax.
Why Consider Prof. Moshe Inbar?
Prof. Inbar brings over 30 years of focused medical oncology experience to the care of patients with gastrointestinal, colorectal, gastric and pancreatic cancers. His combination of clinical depth, academic affiliation and a multidisciplinary approach makes him a relevant choice for complex second opinions and treatment planning.
Areas of Specialisation
Senior medical oncologist focused on gastrointestinal, colorectal and solid tumour management
Prof. Inbar's clinical specialisation spans the full range of solid tumour oncology, with particular depth in gastrointestinal cancers. His practice integrates systemic therapy, molecular profiling and multidisciplinary tumour board planning.
Gastrointestinal Cancer Management
Comprehensive systemic treatment planning for colorectal, gastric, oesophageal and pancreatic cancers.
- arrow_rightChemotherapy planning for localised, locally advanced and metastatic disease
- arrow_rightMolecular marker review including RAS, BRAF, MSI/MMR and HER2 testing
- arrow_rightAnti-EGFR and anti-VEGF targeted therapy assessment
- arrow_rightNeoadjuvant and adjuvant treatment planning with surgical and radiation teams
- arrow_rightBiomarker-based treatment selection including HER2, PD-L1 and MSI/MMR status
- arrow_rightSystemic therapy combinations โ chemotherapy, targeted therapy and immunotherapy
- arrow_rightPerioperative and palliative treatment planning
- arrow_rightResectable, borderline resectable and metastatic pancreatic cancer management
- arrow_rightNeoadjuvant chemotherapy before surgery when appropriate
- arrow_rightSystemic therapy for advanced disease and supportive care coordination
Immunotherapy and Biomarker-Based Treatment
Evaluation of immunotherapy suitability in selected patients based on molecular findings and cancer type.
- arrow_rightMSI-high and mismatch repair deficient tumour identification for checkpoint inhibitor eligibility
- arrow_rightPD-L1 testing review in gastric and GEJ cancers
- arrow_rightEvidence-based counselling on immunotherapy candidacy
- arrow_rightBiomarker-guided selection of approved targeted agents
- arrow_rightTreatment planning for HER2-positive and RAS/BRAF-mutant tumours
Breast and Urogenital Cancer
Medical oncology for breast cancer and urological malignancies as part of a broad solid tumour practice.
- arrow_rightChemotherapy, hormonal therapy and targeted treatment planning
- arrow_rightAdjuvant and neoadjuvant therapy co-ordination with surgical teams
- arrow_rightSystemic treatment planning for selected genitourinary malignancies
- arrow_rightMultidisciplinary management in collaboration with urological surgeons
Procedures Performed
Clinical services and treatment approaches at Tel Aviv Sourasky Medical Center
Prof. Inbar's clinical activity covers the full range of medical oncology services for solid tumours, with particular strength in gastrointestinal cancer management.
Systemic Chemotherapy
Medical OncologyEvidence-based chemotherapy protocols for colorectal, gastric, pancreatic and other solid tumours across disease stages.
Targeted Therapy
Targeted TherapyMolecularly guided treatment planning using biomarker results to identify suitable targeted agents.
Immunotherapy Assessment
Medical OncologyEvaluation of immunotherapy candidacy in selected GI cancer patients based on MSI, MMR, and PD-L1 status.
Second Opinion Consultations
Second OpinionIndependent expert review of pathology, imaging, molecular reports and prior treatment plans.
Multidisciplinary Tumour Board Planning
MultidisciplinaryInvolvement in multidisciplinary tumour board discussions for complex cancer cases requiring coordinated care.
Research & Publications
Academic contributions in GI oncology, breast cancer and chemoradiation
Prof. Inbar's research interests span gastrointestinal oncology, breast cancer, rectal cancer and biomarker-driven treatment strategies. His academic work is underpinned by his affiliation with Tel Aviv University and longstanding involvement in clinical oncology research.
A more detailed publication list and research profile may be available on request through the hospital or through CancerFax case coordination.
Education & Training
Prof. Inbar completed his medical training at Tel Aviv University and undertook international training in oncology in the United States, building a strong foundation for his career in medical oncology.
Clinical Experience
Prof. Moshe Inbar has spent more than 30 years practising medical oncology at Tel Aviv Sourasky Medical Center, one of Israel's leading academic hospitals, building deep expertise in gastrointestinal and solid tumour oncology.
Languages & International
Prof. Inbar conducts consultations in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients who require assistance.
CancerFax can coordinate professional medical interpreter support for patients consulting in Arabic, Russian, or other languages.
How CancerFax Helps You Access Dr. Moshe Inbar
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Moshe Inbar's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Moshe Inbar's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Moshe Inbar before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Moshe Inbar's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Moshe Inbar's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Moshe Inbar's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Moshe Inbar
CancerFax can coordinate medical record review and consultation support for international patients seeking an expert opinion from Prof. Inbar at Tel Aviv Sourasky Medical Center. This is subject to hospital availability and case acceptance. CancerFax handles case preparation, document translation where needed, and communication with the hospital.
Prof. Inbar is a senior medical oncologist specialising in gastrointestinal cancers, including colorectal cancer, gastric cancer, gastroesophageal junction cancer, oesophageal cancer and pancreatic cancer. He also treats breast cancer and urogenital cancers, and provides second opinions for complex solid tumour cases.
Submit your complete medical records through CancerFax using the Send Your Reports button. The CancerFax team will review your case, prepare a structured medical summary, and coordinate the consultation with Prof. Inbar's team. Relevant documents include biopsy reports, molecular testing, CT or PET-CT scans, prior treatment summaries and blood results.
Yes. Prof. Inbar provides expert guidance on immunotherapy suitability in selected patients. In colorectal cancer, eligibility for checkpoint inhibitors depends on MSI or mismatch repair status. In gastric and gastroesophageal cancers, PD-L1 status, HER2 status and MSI findings guide treatment decisions. Prof. Inbar reviews these biomarker results as part of his treatment planning.
For a meaningful second opinion, patients should share all available records including the diagnosis summary, histopathology report, immunohistochemistry report, molecular or NGS testing if available, CT or PET-CT scan reports, complete prior treatment history including chemotherapy protocols, surgery notes if applicable, and recent blood tests. CancerFax can help organise and translate documents if needed.
Prof. Moshe Inbar is associated with Tel Aviv Sourasky Medical Center, also widely known as Ichilov Hospital, located in Tel Aviv, Israel. It is one of Israel's leading academic medical centres offering advanced oncology diagnosis, treatment and multidisciplinary cancer care.
Connect with Moshe Inbar Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.